Intrinsiqq
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc.

MLYS

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1.21B
EPS-$4.37
P/E-3.13
P/FCF-7.91
EV/EBITDA-2.84
FCF Yield–
Div. Yield–
Net Debt/FCF0.7x
Mineralys Therapeutics, Inc. intrinsic value
52-Week Range
$13.66$40.74

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$370M

▲ +13.0% YoY

Op. Margin

–

ROIC

-52.64%

▲ +38.1pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$153M

▲ +14.4% YoY

Op. Cash Flow (TTM)

-$153M

▲ +14.4% YoY

Net Debt

-$101M

Net Cash Position

Cash & Equiv.

$101M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with MLYS

CompareIntrinsic value
INVAInnoviva Inc.
$18.41+0.00%60
PAHCPhibro Animal Health Corporation
$33.29-2.32%57
NUVBNuvation Bio Inc.
$3.80-0.26%10
RAREUltragenyx Pharmaceutical Inc.
$16.48-4.30%40
PRGOPerrigo Company plc
$15.94-0.62%17
RCUSArcus Biosciences Inc.
$15.62-1.01%10
XNCRXencor Inc.
$33.26-2.21%11
VRDNViridian Therapeutics Inc.
$29.93-4.80%40

Held by ETFs

MLYS is in 37 US ETFs. The largest of them, with MLYS's weight in each:

Mineralys Therapeutics (MLYS) in two numbers

Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-3.13
Negative: a loss over the last twelve months. Price to free cash flow -7.91.
Financials

Questions about Mineralys Therapeutics

Does Mineralys Therapeutics (MLYS) pay a dividend?

No. Mineralys Therapeutics (MLYS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 29 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in MLYS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MLYS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.